CAPELLO JEFFREY D
CAPELLO JEFFREY D's purchase track record
CAPELLO JEFFREY D has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/22/2025 | NEOG | $100K | +5.7% | +24.2% | +27.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
Transaction History
| NEOG | ▲ Buy | Grant | 9,804 | $120K | 10/1/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,816 | $0 | 6/18/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 1,976 | $0 | 6/13/2026 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 2,025 | $13K | 10/27/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 1,777 | $11K | 10/27/2025 | View on chart |
| NEOG | ▲ Buy | Grant | 19,769 | $120K | 10/23/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 2,071 | $12K | 10/7/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,120 | $0 | 6/20/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 1,977 | $0 | 6/13/2025 | View on chart |
| NEOG | ▲ Buy | Open Market | 20,712 | $100K | 4/22/2025 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 1,776 | $25K | 10/28/2024 | View on chart |
| NEOG | ▲ Buy | Grant | 6,075 | $82K | 10/24/2024 | View on chart |
| NEOG | ▲ Buy | Option Exercise | 2,070 | $31K | 10/7/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 1,976 | $0 | 6/13/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Neogen Corp reports earnings, faces FDA warning, outlines growth plan
Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.
Neogen Corp reports earnings, faces FDA warning, outlines growth plan. Neogen released its 2027 Q1 earnings presentation, highlighting recent revenue trends and upcoming initiatives. The company also disclosed an FDA warning related to a contaminated veterinary product, which may affect short‑term perception. At its recent Investor Day, management outlined a plan to reach a 30% EBITDA margin by 2031 and emphasized growing demand for food‑safety solutions. Analysts continue to note the stock’s recent price movement amid these developments.